New drug shows promise in early trial for rare blood disorder
NCT ID NCT05889299
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tested an experimental drug called OMS906 (zaltenibart) in 15 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease where red blood cells break apart. The main goal was to check safety and how the body handles the drug. Researchers also looked for early signs that the drug might reduce red blood cell destruction and improve anemia. The study included patients not on other treatments and those already on standard therapy but with poor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OMS906 (also called zaltenibart), an experimental biologic drug
What this could lead to
If it works, this could point toward a new treatment option for PNH that helps control red blood cell breakdown and anemia.
What could go wrong
This is a very early, small study (15 people) focused on safety, not proof of effectiveness. The drug may not work in larger trials or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Omeros Investigational Site
Kyiv, Ukraine